计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V129241-1g |
1g |
现货 ![]() |
| |
| V129241-5g |
5g |
现货 ![]() |
| |
| V129241-25g |
25g |
现货 ![]() |
| |
| V129241-100g |
100g |
现货 ![]() |
|
| 别名 | 缬沙坦 | N-(1-氧代戊基)-N-[[2'-(2H-四唑-5-基)[1,1'-联苯]-4-基]甲基]-L-缬氨酸 |
|---|---|
| 英文别名 | HSDB 7519 | Valsartan [USAN:USP:INN:BAN] | 80M03YXJ7I | Tareg | VALSARTAN (USP-RS) | MLS001424088 | VALSARTAN [INN] | ENTRESTO COMPONENT VALSARTAN | Spectrum_001796 | Miten | VALSARTAN [MART.] | VALSARTAN [VANDF] | VALSARTAN [EMA EPAR] | VALSARTAN [HSDB] |
| 规格或纯度 | Moligand™, ≥98%(HPLC) |
| 英文名称 | Valsartan |
| 生化机理 | 缬沙坦是一种血管紧张素II 1型(AT1)受体拮抗剂和抗高血压药。缬沙坦可以防止由血压突然升高导致的心脏病发作和中风。 缬沙坦可降低心脏病发作幸存者的心肌梗死相关并发症。高度选择性,有效的竞争性AT 1受体拮抗剂(K i = 2.38 nM)。在体内显示出降压作用。显示中央和外围效果。口服具有活性 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | AT 1 受体拮抗剂 |
| 备注 | 需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Valsartan是一种血管紧张素II受体拮抗剂,IC50在39.5到116 μM之间。使用缬沙坦治疗小鼠,以研究Ang II依赖性途径对醛固酮相关作用的影响。 Valsartan is an angiotensin II receptor antagonist with IC50 of ranging from 39.5 to 116 μM. Valsartan is an orally active specific angiotensin II receptor blocker used for the treatment of hypertension |
| 纯度 | ≥98%(HPLC) |
| ALogP | 4.4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| EC号 | 604-045-2, 695-249-0 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid |
| INCHI | 1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 |
| InChi Key | ACWBQPMHZXGDFX-QFIPXVFZSA-N |
| Smiles | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O |
| Isomeric SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O |
| 关联CAS | 137862-53-4 |
| NSC Number | 758927 |
| MeSH Entry Terms | 48933, CGP;CGP 48933;Diovan;Kalpress;Miten;N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine;Nisis;Provas;Tareg;Vals;valsartan |
| 分子量 | 435.52 |
| Reaxy-Rn | 24721853 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24721853&ln= |
| 溶解性 | Soluble in Ethanol and Methanol |
|---|---|
| 敏感性 | 对湿度敏感 |
| 比旋光度 | -65°C |
| 熔点 | 117°C |
| 分子量 | 435.500 g/mol |
| XLogP3 | 4.400 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 435.227 Da |
| 单同位素质量Monoisotopic Mass | 435.227 Da |
| 拓扑极表面积Topological Polar Surface Area | 112.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 608.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H361: 怀疑破坏生育力或未出生的孩子 H412: 对水生生物有害并具有长期持续影响 |
| 预防措施声明 |
P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P318: 如果暴露或担心,请就医。 |
| WGK Germany | 3 |
| Merck Index | 9916 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 | |
| 分析证书 | V129241 |
| 1. Qinglin Wang, Hao Yuan, Xinyue Pan, Yiling Yang, Xiaosong Ma, Yahui Guo. (2024) Synthesis of silver nanoclusters using a double-stranded DNA template and its application for captopril detection. JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 126 (105825). [10.1016/j.jfca.2023.105825] |
| 2. Huimin Zhou, Zhiwei Qiu, Jin Zeng, Ruobin Dai, Zhiwei Wang. (2023) Ultra-permeable polyamide nanofiltration membrane modified by hydrophilic-hydrophobic alternated lignocellulosic nanofibrils for efficient water reuse. JOURNAL OF MEMBRANE SCIENCE, 688 (122125). [10.1016/j.memsci.2023.122125] |
| 3. Zhiren Zou, Qiang Huang, Xiaobo Li, Xianzhi Liu, Lina Yin, Yunjie Zhao, Guang Liang, Wenqi Wu. (2023) Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 188 (106526). [PMID:37442486] [10.1016/j.ejps.2023.106526] |
| 4. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Lina Wang, Wen Kou, Xin’an Wu. (2023) Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells, Activation of the TGF-β1/Smad2/3 Pathway, and Aggravation of Oxidative Stress. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (13): (10839). [PMID:37446016] [10.3390/ijms241310839] |
| 5. Yupeng Shi, Mengyang Zhou, Shuo Zhao, Haotian Li, Wenhao Wang, Jingliang Cheng, Lin Jin, Yifei Wang. (2023) Janus amphiphilic nanofiber membranes synergistically drive antibacterial and anti-inflammatory strategies for skin wound healing. MATERIALS & DESIGN, 227 (111778). [10.1016/j.matdes.2023.111778] |
| 6. Qiang Huang, Zhiren Zou, Xiaobo Li, Qinwen Xiao, Guang Liang, Wenqi Wu. (2023) Poly (amino acid)s as new co-formers in amorphous solid dispersion. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 634 (122645). [PMID:36706970] [10.1016/j.ijpharm.2023.122645] |
| 7. Mingkang Zhang, Ruirui Cui, Yan Zhou, Yanrong Ma, Yongwen Jin, Xueyan Gou, Jinru Yang, Xin’an Wu. (2023) Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. TOXICOLOGY, 483 (153387). [PMID:36464070] [10.1016/j.tox.2022.153387] |
| 8. Lin Chen, Li Ge, Qinghui Liang, Zhenbo Zhao, Kedi Yang. (2022) Eutectic solvents formed by (+)-DTTA and L-menthol as novel chiral recognition and separation media for enantioselective extraction of valsartan enantiomers. JOURNAL OF MOLECULAR LIQUIDS, 368 (120818). [10.1016/j.molliq.2022.120818] |
| 9. Ke Lin, Wu Luo, Na Yang, Lan Su, Hao Zhou, Xiang Hu, Yi Wang, Zia A. Khan, Weijian Huang, Gaojun Wu, Guang Liang. (2022) Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation. INTERNATIONAL IMMUNOPHARMACOLOGY, 112 (109218). [PMID:36116148] [10.1016/j.intimp.2022.109218] |
| 10. Wang Yiran, Shi Jihua, Dai Dapeng, Cai Jianping, Wang Shuanghu, Hong Yun, Zhou Shan, Zhao Fangling, Zhou Quan, Geng Peiwu, Zhou Yunfang, Xu Xue, Luo Qingfeng. (2022) Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo. Frontiers in Pharmacology, 13 [PMID:36052128] [10.3389/fphar.2022.909168] |
| 11. Yan Zhou, Mengmeng Wei, Mingkang Zhang, Jianping Zhang, Fabing Tang, Xin’an Wu. (2022) Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. TOXICOLOGY LETTERS, 359 (10). [PMID:35114312] [10.1016/j.toxlet.2022.01.018] |
| 12. Xiao Juan Liu, Yang Zhang, Xue Zhong Wang. (2020) Study on Co-Crystallization of LCZ696 Using In Situ ATR-FTIR and Imaging. Crystals, 10 (10): (922). [10.3390/cryst10100922] |
| 13. Qi Liang, Xiaoying Fu, Jianfeng Zhang, Jiaxue Hao, Gangjun Feng, Jing Wang, Qian Li, Faizan Ahmad, Xinfeng Zhao. (2020) Immobilized angiotensin II type I receptor: A powerful method of high throughput screening for antihypertensive compound identification through binding interaction analysis. JOURNAL OF CHROMATOGRAPHY A, 1620 (461003). [PMID:32156458] [10.1016/j.chroma.2020.461003] |
| 14. Yi-Lin Sun, Peng-Hui Li, Ling Shi, Wan-Zhen Su, De-Sheng Li, Gen-Long Xue, Yue Zhao, Chang-Zhu Li, Ying Li, Yang Zhou, Shang-Xuan Li, Yang Zhang, Yan-Jie Lu, Zhen-Wei Pan. (2018) Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 29 (10): (1436-1443). [PMID:30016000] [10.1111/jce.13697] |
| 15. Xiaohua Xu, Yongzhi Xu, Shengqiang Liang. (2024) Analytical Interference in Chemiluminescence Assay–Measured Angiotensin I, Angiotensin II, Aldosterone, and Renin. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 38 (10): (e25045). [PMID:38822626] [10.1002/jcla.25045] |
| 16. Jia-Huan He, Xiang-Jun Li, Shi-Peng Wang, Xia Guo, Hao-Xuan Chu, Han-Chi Xu, Yu-Shi Wang. (2024) Eugenol Inhibits Ox-LDL-Induced Proliferation and Migration of Human Vascular Smooth Muscle Cells by Inhibiting the Ang II/MFG-E8/MCP-1 Signaling Cascade. Journal of Inflammation Research, [PMID:38328560] [10.2147/JIR.S446960] |
| 17. Huixiang Zhang, Yang Zhang, Fumin Xue, Hui Chen, Zhenguo Gao, Shichao Du, Yan Wang. (2024) Insight into the dissolution behavior of valsartan (form E) in twelve pure solvents: Solubility, modelling and molecular simulation. JOURNAL OF MOLECULAR LIQUIDS, 402 (124774). [10.1016/j.molliq.2024.124774] |
| 18. Wen Luo, Zhenzhen Li, Junjie Che, Xinyao Li, Huali Zhang, Jinxiu Tian, Chunyang Wang, GuiYing Li, Lin Jin. (2024) Near-Infrared Responsive Nanocomposite Hydrogel Dressing with Anti-Inflammation and Pro-Angiogenesis for Wound Healing. ACS Applied Materials & Interfaces, 16 (27): (34720-34731). [PMID:38934381] [10.1021/acsami.4c06193] |
| 19. Chenglin Liang, Ge Zhang, Linlin Guo, Xinyi Ding, Heng Yang, Hongling Zhang, Zhenzhong Zhang, Lin Hou. (2024) Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy. Asian Journal of Pharmaceutical Sciences, (100888). [PMID:38434719] [10.1016/j.ajps.2024.100888] |
| 20. Detao Li, Wenqian Chen, Limin Zhou, Li Xu, Feiqiang He, Jerry Y Y Heng, Hamza Shehzad, Jinbo Ouyang. (2024) Uncovering Cocrystal Formation and Competition Mechanism of Polyhydroxy Natural Products: Cases of Quercetin, Hesperidin, Resveratrol, and Curcumin. CRYSTAL GROWTH & DESIGN, 24 (11): (4652-4667). [10.1021/acs.cgd.4c00291] |